Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus XACIATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus XACIATO.
CLEOCIN HYDROCHLORIDE vs XACIATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, thereby interfering with peptide bond formation and chain elongation.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide bond formation.
150-450 mg orally every 6 hours (oral capsules). Maximum dose: 1.8 g/day.
Administer one vaginal gel (50 mg clindamycin) intravaginally as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 to 3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8.5 hours. No significant change in renal impairment.
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. Half-life may be prolonged in patients with severe hepatic impairment or neonates.
Approximately 10% of the active drug is excreted in urine as unchanged clindamycin; about 3.6% in feces; remainder is metabolized primarily in liver. Renal excretion accounts for ~10% of elimination, biliary/fecal route accounts for ~90% including metabolites.
Clindamycin is primarily excreted via bile (approximately 85% of the dose as metabolites and parent drug) and feces (10%), with renal excretion accounting for less than 10%.
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic